The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
An Overview of Drug Discovery and Development
Abstract
A new medicine will take an average of 10-15 years and more than US$2 billion before it can reach the pharmacy shelf. Traditionally, drug discovery relied on natural products as the main source of new drug entities, but was later shifted toward high-throughput synthesis and combinatorial chemistry-based development. New technologies such as ultra-high-throughput drug screening and artificial intelligence are being heavily employed to reduce the cost and the time of early drug discovery, but they remain relatively unchanged. However, are there other potentially faster and cheaper means of drug discovery? Is drug repurposing a viable alternative? In this review, we discuss the different means of drug discovery including their advantages and disadvantages.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Natural products as sources of new drugs from 1981 to 2014
Newman, D. J., & Cragg, G. M. (2016) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5b01055 · Cited by 5,858
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Natural products: A continuing source of novel drug leads
Cragg, G. M., & Newman, D. J. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.02.008 · Cited by 2,906
Drug Discovery: A Historical Perspective
Drews, J. (2000) · Science · doi:10.1126/science.287.5460.1960 · Cited by 2,760
A comprehensive map of molecular drug targets
Santos, R., Ursu, O., Gaulton, A., Bento, A. P., Donadi, R. S., Bologa, C. G., Karlsson, A., Al-Lazikani, B., Hersey, A., Oprea, T. I., et al. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.230 · Cited by 2,427
Computational Methods in Drug Discovery
Sliwoski, G., Kothiwale, S., Meiler, J., & Lowe, E. W. (2014) · Pharmacological Reviews · doi:10.1124/pr.112.007336 · Cited by 2,160
Rational design of potent sialidase-based inhibitors of influenza virus replication
von Itzstein, M., Wu, W.-Y., Kok, G. B., Pegg, M. S., Dyason, J. C., Jin, B., Van Phan, T., Smythe, M. L., White, H. F., Oliver, S. W., et al. (1993) · Nature · doi:10.1038/363418a0 · Cited by 1,862
Natural products in drug discovery
Harvey, A. L. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.07.004 · Cited by 1,832
Structural mechanism for statin inhibition of HMG-CoA reductase
Istvan, E. S., & Deisenhofer, J. (2001) · Science · doi:10.1126/science.1059344 · Cited by 1,644
Prodrugs: design and clinical applications
Rautio, J., Kumpulainen, H., Heimbach, T., Oliyai, R., Oh, D., Järvinen, T., & Savolainen, J. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2468 · Cited by 1,630
Proteasome inhibitors: a novel class of potent and effective antitumor agents.
Adams, J., Palombella, V. J., Sausville, E. A., Johnson, J. I., Destree, A. T., Lazarus, D. D., Maas, J., Pien, C. S., Prakash, S., & Elliott, P. J. (1999) · PubMed · Cited by 1,477
Natural Products for Drug Discovery in the 21st Century: Innovations for Novel Drug Discovery
Thomford, N. E., Senthebane, D. A., Rowe, A., Munro, D., Seele, P., Maroyi, A., & Dzobo, K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061578 · Cited by 1,241
Natural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,075
Boolell, M., Mj, A., Sa, B., Gepi-Attee, S., Muirhead, G. J., Naylor, A. M., Ih, O., & Gingell, C. (1996) · PubMed · Cited by 1,067
Fogel, D. B. (2018) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2018.08.001 · Cited by 1,035
Role of computer-aided drug design in modern drug discovery
Macalino, S. J. Y., Gosu, V., Hong, S., & Choi, S. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0640-5 · Cited by 762
A New Golden Age of Natural Products Drug Discovery
Shen, B. (2015) · Cell · doi:10.1016/j.cell.2015.11.031 · Cited by 635
Review of Drug Repositioning Approaches and Resources
Xue, H., Li, J., Xie, H., & Wang, Y. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.24612 · Cited by 614
Greer, J., Erickson, J. W., Baldwin, J. J., & Varney, M. D. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00034a001 · Cited by 282
Engineering Robust Production Microbes for Large-Scale Cultivation
Wehrs, M., Tanjore, D., Eng, T., Lievense, J., Pray, T. R., & Mukhopadhyay, A. (2019) · Trends in Microbiology · doi:10.1016/j.tim.2019.01.006 · Cited by 279
Peptide therapeutics from venom: Current status and potential
Pennington, M. W., Czerwinski, A., & Norton, R. S. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.09.029 · Cited by 278
Kikuchi, T., Tottori, K., Uwahodo, Y., Hirose, T., Miwa, T., Oshiro, Y., & Morita, S. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10600-9 · Cited by 276
Drug development: Lessons from nature
Mathur, S., & Hoskins, C. (2017) · Biomedical Reports · doi:10.3892/br.2017.909 · Cited by 269
Natural product derived privileged scaffolds in drug discovery
Davison, E. K., & Brimble, M. A. (2019) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.12.007 · Cited by 247
Marrakchi, H., Lanéelle, G., & Quémard, A. (2000) · Microbiology · doi:10.1099/00221287-146-2-289 · Cited by 238
Aboud-Pirak, E., Hurwitz, E., Pirak, M., Bellot, F., Schlessinger, J., & Sela, M. (1988) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/80.20.1605 · Cited by 231
Inhibition of Angiogenesis by the Antifungal Drug Itraconazole
Chong, C. R., Xu, J., Lu, J., Bhat, S., Sullivan, D. J., & Liu, J. O. (2007) · ACS Chemical Biology · doi:10.1021/cb600362d · Cited by 210
Cheminformatic comparison of approved drugs from natural product versus synthetic origins
Stratton, C. F., Newman, D. J., & Tan, D. S. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.07.014 · Cited by 191
Amoxycillin: A new Semi-synthetic Penicillin
Sutherland, R., Croydon, E. A. P., & Rolinson, G. N. (1972) · BMJ · doi:10.1136/bmj.3.5817.13 · Cited by 178
Whittington, R., & Faulds, D. (1993) · Drugs · doi:10.2165/00003495-199346030-00009 · Cited by 176
An update on Drug Repurposing: Re-written saga of the drug’s fate
GNS, H. S., GR, S., Murahari, M., & Krishnamurthy, M. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.11.127 · Cited by 161
Anticancer Activity of Metformin: A Systematic Review of the Literature
Aljofan, M., & Riethmacher, D. (2019) · Future Science OA · doi:10.2144/fsoa-2019-0053 · Cited by 160
Self-citationDefining the difference: What Makes Biologics Unique.
Morrow, T., & Felcone, L. H. (2004) · Europe PMC (PubMed Central) · Cited by 148
Ueda, H., Nakajima, H., Hori, Y., Goto, T., & OKUHARA, M. (1994) · Bioscience Biotechnology and Biochemistry · doi:10.1271/bbb.58.1579 · Cited by 144
Estimating the clinical cost of drug development for orphan versus non-orphan drugs
Jayasundara, K., Hollis, A., Krahn, M. D., Mamdani, M., Hoch, J. S., & Grootendorst, P. V. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-018-0990-4 · Cited by 127
Spencer, C. M., & Faulds, D. M. (2000) · Drugs · doi:10.2165/00003495-200060020-00006 · Cited by 127
Screening of natural products for drug discovery
Lahlou, M. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.5.697 · Cited by 121
Computational and Practical Aspects of Drug Repositioning
Oprea, T. I., & Overington, J. P. (2015) · Assay and Drug Development Technologies · doi:10.1089/adt.2015.29011.tiodrrr · Cited by 119
Rituximab: A New Therapeutic Monoclonal Antibody for Non‐Hodgkin's Lymphoma
Scott, S. D. (1998) · Cancer Practice · doi:10.1046/j.1523-5394.1998.006003195.x · Cited by 105
Abdolmaleki, A., Ghasemi, J. B., & Ghasemi, F. (2017) · Current Drug Targets · doi:10.2174/1389450117666160101120822 · Cited by 104
Complex phenotypic assays in high-throughput screening
Clemons, P. A. (2004) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2004.04.002 · Cited by 102
Buchser, W., Collins, M. A., Garyantes, T. K., Guha, R., Haney, S. A., Lemmon, V., Li, Z., & Trask, O. J. (2014) · Cited by 101
Cell-Based Assay Design for High-Content Screening of Drug Candidates
Nierode, G. J., Kwon, P. S., Dordick, J. S., & Kwon, S. (2016) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.1508.08007 · Cited by 97
Annang, F. B., Pérez‐Moreno, G., García‐Hernández, R., Cordón-Obras, C., Martı́n, J., Tormo, J. R., Rodríguez, L., de Pedro, N., Gómez‐Pérez, V., Valente, M., et al. (2014) · SLAS DISCOVERY · doi:10.1177/1087057114555846 · Cited by 94
Improved Classification of Blood-Brain-Barrier Drugs Using Deep Learning
Miao, R., Xia, L.-Y., Chen, H.-H., Huang, H.-H., & Liang, Y. (2019) · Scientific Reports · doi:10.1038/s41598-019-44773-4 · Cited by 91
Wang, L., Gu, Q., Zheng, X., Ye, J., Liu, Z., Li, J., Hu, X., Hagler, A. T., & Xu, J. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci400322j · Cited by 76
A review of validation strategies for computational drug repositioning
Brown, A. S., & Patel, C. J. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbw110 · Cited by 70
Challenges and Opportunities in High Throughput Screening: Implications for New Technologies
Major, J. S. (1998) · SLAS DISCOVERY · doi:10.1177/108705719800300102 · Cited by 61
Digoxin comes from Digitalis lanata
Hollman, A. (1996) · BMJ · doi:10.1136/bmj.312.7035.912 · Cited by 56
Development and use of palivizumab (Synagis): a passive immunoprophylactic agent for RSV
Pollack, P. F., Groothuis, J. R., & Barbarotto, G. M. (2002) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-002-0178-6 · Cited by 53
A high-throughput in vitro model of human embryo attachment
Ho, H.-T., Singh, H., Aljofan, M., & Nie, G. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2012.01.116 · Cited by 44
Self-citationAtangcho, L., Navaratna, T. A., & Thurber, G. M. (2018) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2018.11.008 · Cited by 33
Journal of Antivirals & Antiretrovirals
Aljofan, M., Lo, M. K., Rota, P. A., et al. (2010) · Journal of Antivirals & Antiretrovirals · doi:10.4172/jaa.1000014 · Cited by 24
Self-citationComputer-Aided Drug Design: Using Numbers to Your Advantage
Faver, J. C., Ucisik, M. N., Yang, W. Y., & Merz, K. M. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4002634 · Cited by 24
Assessing Pharmaceutical Research and Development Costs
DiMasi, J. A. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.8703 · Cited by 23
Soleilhac, E., Nadon, R., & Lafanéchère, L. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460440903544456 · Cited by 19
Mofidifar, S., Sohraby, F., Bagheri, M., & Aryapour, H. (2018) · Biogerontology · doi:10.1007/s10522-018-9744-x · Cited by 16
Aljofan, M., & Gaipov, A. (2019) · Electronic Journal of General Medicine · doi:10.29333/ejgm/108679 · Cited by 9
Self-citation
Cited by
Molecular photoswitches in aqueous environments
Volarić, J., Szymanski, W., Simeth, N. A., & Feringa, B. L. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00547a · Cited by 438
Toward better drug discovery with knowledge graph
Zeng, X., Tu, X., Liu, Y., Fu, X., & Su, Y. (2022) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2021.09.003 · Cited by 229
Xu, Z., Ren, F., Wang, P., Cao, J., Tan, C., Ma, D., Zhao, L., Dai, J., Ding, Y., Fang, H., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03743-2 · Cited by 180
“The process of developing novel therapeutics is increasingly slow and costly 1 , with an average of US$2–3 billion spent over the course of 10–15 years to bring a new drug to market 2 .”
Advancing pharmaceutical research: A comprehensive review of cutting-edge tools and technologies
Chen, J., Lin, A., & Luo, P. (2024) · Current Pharmaceutical Analysis · doi:10.1016/j.cpan.2024.11.001 · Cited by 112
RELATION: A Deep Generative Model for Structure-Based De Novo Drug Design
Wang, M., Hsieh, C.-Y., Wang, J., Wang, D., Weng, G., Shen, C., Yao, X., Bing, Z., Li, H., Cao, D., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00732 · Cited by 99
Metadata
- Authors
- Berdigaliyev, N., & Aljofan, M.
- Venue
- Future Medicinal Chemistry
- Publisher
- Informa UK Limited
- Published
- 2020-04-09
- Volume
- 12
- Issue
- 10
- Pages
- 939-947
- ISSN
- 1756-8919 (ISSN-L)
- 1756-8927
- OpenAlex
- W3016077459
- Cited by
- 396
- References
- 59
- FWCI
- 15.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.